MDM2-IN-6
MDM2-IN-6 is an orally active MDM2 inhibitor with an IC50 of 3.7 nM. MDM2-IN-6 can serve as a target protein ligand for the synthesis of MDM2 PROTAC degraders, such as SJYHJ-048 (HY-188657). MDM2-IN-6 exhibits anticancer activity against osteosarcoma, leukemia, prostate cancer, and colon cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1818393-09-7
- Formel: C32H34Cl2FN3O4
- Molecular Weight:614.53
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
MDM2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SJSA-1 | IC50 |
0.089 μM
|
Cell growth inhibition against human SJSA-1 osteosarcoma cells with wild-type p53.
Cell growth inhibition against human SJSA-1 osteosarcoma cells with wild-type p53.
|
PMC5394527 |
| SAOS-2 | IC50 |
26.7 μM
|
Cell growth inhibition against human Saos2 osteosarcoma cells with p53 null status.
Cell growth inhibition against human Saos2 osteosarcoma cells with p53 null status.
|
PMC5394527 |
| RS4-11 | IC50 |
62 nM
|
Cell growth inhibition against human RS4;11 leukemia cells with wild-type p53.
Cell growth inhibition against human RS4;11 leukemia cells with wild-type p53.
|
PMC5394527 |
| LNCaP | IC50 |
36 nM
|
Cell growth inhibition against human LNCaP prostate cancer cells with wild-type p53.
Cell growth inhibition against human LNCaP prostate cancer cells with wild-type p53.
|
PMC5394527 |
| PC-3 | IC50 |
12.3 μM
|
Cell growth inhibition against human PC3 prostate cancer cells with p53 null status.
Cell growth inhibition against human PC3 prostate cancer cells with p53 null status.
|
PMC5394527 |
| HCT-116 | IC50 |
137 nM
|
Cell growth inhibition against human HCT116 colon cancer cells with wild-type p53.
Cell growth inhibition against human HCT116 colon cancer cells with wild-type p53.
|
PMC5394527 |
In Vitro
MDM2-IN-6 inhibits the growth of Saos2 p53-deficient osteosarcoma cells, IC50 = 26.7 μM[1].
MDM2-IN-6 inhibits the growth of RS4;11 leukemia cells, IC50 = 62 nM[1].
MDM2-IN-6 inhibits the growth of LNCaP prostate cancer cells, IC50 = 36 nM[1].
MDM2-IN-6 inhibits the growth of PC3 p53-deficient prostate cancer cells, IC50 = 12.3 μM[1].
MDM2-IN-6 inhibits the growth of HCT116 colon cancer cells, IC50 = 137 nM[1].
MDM2-IN-6 inhibits the growth of HCT116 p53−/− colon cancer cells, IC50 = 14 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SJSA-1 xenograft tumor[1]
-
Dosage:100 mg/kg
-
Administration:p.o.
-
Result:In SJSA-1 xenograft efficacy experiments, 100 mg/kg once daily for 14 days produced only very moderate/moderate tumor growth inhibition and no tumor regression.
Antitumor efficacy was recorded as no regression.
-
Animal Model:SJSA-1 xenograft tumor[1]
-
Dosage:100 mg/kg
-
Administration:p.o.
-
Result:Oral administration at 100 mg/kg induced only modest p53 activation and no cleavage of PARP or caspase-3 in SJSA-1 xenograft tumor tissue at 6 and 24 h.
Parmacokinetics
Chemical Information
-
CAS. Nr. 1818393-09-7
-
Molecular Weight 614.53
-
Formel C32H34Cl2FN3O4
-
SMILES
O=C(O)C12CCC(NC([C@H]3[C@H](C4=C(F)C(Cl)=CC=C4)[C@]5(C(NC6=C5C=CC(Cl)=C6)=O)C7(CCCCC7)N3)=O)(CC2)CC1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)